Presymptomatic MS or radiologically isolated syndrome should be actively monitored and treated: Commentary

Article Clinical Neurology

Dimethyl Fumarate Delays Multiple Sclerosis in Radiologically Isolated Syndrome

Darin T. Okuda et al.

Summary: This study evaluated the impact of therapeutic intervention in preventing the first symptom manifestation in individuals with radiologically isolated syndrome (RIS), the pre-clinical phase of multiple sclerosis (MS). The results showed that drug treatment significantly reduced the risk of clinical symptoms.

ANNALS OF NEUROLOGY (2023)

添加到收藏夹

Review Clinical Neurology

Secondary Prevention in Radiologically Isolated Syndromes and Prodromal Stages of Multiple Sclerosis

Maria Pia Amato et al.

Summary: Despite significant progress in MS treatment, there are still two major unmet needs: understanding the disease's etiology and designing definitive cures, as well as preventing severe and disabling manifestations. Radiologically isolated syndrome and prodromal MS pose the risk of progressing to overt disease. Implementation of study groups and disease registry are important for conducting informative clinical trials.

FRONTIERS IN NEUROLOGY (2022)

添加到收藏夹

Review Clinical Neurology

Health economics of disease-modifying therapy for multiple sclerosis in the United States

Daniel M. Hartung

Summary: Multiple sclerosis (MS) is a chronic neuroinflammatory condition that is associated with significant disability. The high and rising prices of disease-modifying therapies (DMTs) for MS are a major driver of healthcare expenditures. The cost burden of DMTs negatively affects both healthcare systems and patients.

THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2021)

添加到收藏夹

Article Clinical Neurology